Research
Hormonal
GLP-1 receptor agonists (specifically high-dose liraglutide) prevent the progression from prediabetes to type 2 diabetes in obese individuals.
If you have prediabetes and are overweight, talk to your doctor about GLP-1 medications like liraglutide. They can significantly reduce your risk of developing full-blown type 2 diabetes.
GoodSupportsHIGH confidence
High-dose liraglutide 3.0 mg, used as an obesity drug, has shown an 80% diabetes prevention effect in prediabetes patients.
Why this rating
Based on a cited randomized controlled trial (LEAD-Pred).
Source
Extent of Role: Anti-Diabetic Medications
Jun Hwa Hong · Journal of Korean Diabetes · 2022
DOI 10.4093/jkd.2022.23.3.153
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors and GLP-1 receptor agonists reduce hospitalization for heart failure, chronic kidney disease, and atherosclerotic cardiovascular disease in patients with type 2 diabetes.Strong
- SGLT2 inhibitors reduce the risk of developing diabetes in high-risk patients with heart failure or chronic kidney disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →